Inside 340B Report Podcast

In episode 5 of Inside 340B Report, the editorial team analyzes the 2024 election’s potential impact on the 340B landscape, including how President-elect Donald Trump’s return to the White House and the new GOP-controlled Congress could approach the drug pricing program. The team also discusses Johnson & Johnson’s (J&J) recent lawsuit against the Health Resources and Services Administration (HRSA), marking a pivotal moment in the ongoing 340B rebate model debate.

In episode 4 of Inside 340B Report, the editorial team explores emerging trends in drugmaker contract pharmacy restrictions, legal developments around 340B eligibility calculations and manufacturer audits of covered entities, and how the upcoming congressional and presidential elections could shift the program's future.

In the third episode, the editorial team discusses Johnson & Johnson’s (J&J) proposed rebate model and whether the company’s recent letter to federal officials was truly the end of the rebate discussion or merely a sign of litigation to come. As the November elections near, the team talks about the future of the Inflation Reduction Act (IRA) and potential 340B reform, as well as how both topics were heavily featured at a recent cancer care summit in New York.

In the second episode, host Ted Slafsky, along with Will Newton and Bella Czajkowski, recap major news impacting the 340B program, including the future of manufacturer efforts to convert 340B to a rebate, Sen. Bill Cassidy’s latest inquiry into two drugmakers, pushback from bipartisan House members to the rebate proposal federal 340B legislation and key state developments. 

Key Topics Covered

Johnson & Johnson recently dropped its 340B rebate proposal amid strong enforcement threats from the federal government, but manufacturer efforts to convert the 340B program to a rebate model are likely to continue. The crew discusses the implications of the government’s response to J&J’s proposal and what it means for other manufacturer efforts to pursue 340B rebate models. They also explain how 340B rebates may arise in response to an inquiry from influential Republican Sen. Bill Cassidy, who has often been critical of 340B program growth. 

Key lawmakers with a more favorable view of the 340B program have also been engaged in a flurry of legislative and policy making activity. The crew shares insights into a bipartisan House letter opposing 340B rebates and the status of a Senate bill to restore 340B discounts to contract pharmacies. They also touch on the implications of a children’s Medicaid enrollment bill with 340B provisions and two major updates on state-level battles over contract pharmacy access laws.

In our inaugural episode, Publisher & CEO Ted Slafsky introduces Associate Editors Shannon Young and Will Newton and National Correspondent Bella Czajkowski and explains how our podcast is unique.